Shares of Omeros Corporation (NASDAQ:OMER) traded up 5.7% on Wednesday . The stock traded as high as $12.56 and last traded at $12.56, with a volume of 229,846 shares changing hands. The stock had previously closed at $11.88.

Several analysts recently weighed in on the company. Maxim Group restated a “buy” rating and set a $30.00 target price on shares of Omeros Corporation in a research note on Thursday, July 28th. Zacks Investment Research downgraded Omeros Corporation from a “hold” rating to a “sell” rating in a research note on Wednesday, July 13th. FBR & Co restated an “outperform” rating and set a $38.00 target price on shares of Omeros Corporation in a research note on Wednesday, June 29th. WBB Securities restated a “buy” rating and set a $75.00 target price on shares of Omeros Corporation in a research note on Tuesday, June 14th. Finally, Cantor Fitzgerald assumed coverage on Omeros Corporation in a research note on Thursday, June 2nd. They set a “buy” rating and a $21.00 target price for the company. One investment analyst has rated the stock with a sell rating and nine have assigned a buy rating to the stock. Omeros Corporation currently has a consensus rating of “Buy” and a consensus price target of $38.22.

The company’s market capitalization is $488.80 million. The stock has a 50-day moving average price of $11.15 and a 200 day moving average price of $12.14.

Omeros Corporation (NASDAQ:OMER) last released its earnings results on Tuesday, May 10th. The biopharmaceutical company reported ($0.54) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.43) by $0.11. The company earned $7.40 million during the quarter, compared to analyst estimates of $8.79 million. The business’s revenue was up 1797.4% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.51) earnings per share. Equities analysts predict that Omeros Corporation will post ($1.76) earnings per share for the current year.

In related news, VP Marcia S. Kelbon sold 15,900 shares of Omeros Corporation stock in a transaction dated Friday, July 15th. The stock was sold at an average price of $11.50, for a total value of $182,850.00. Following the sale, the vice president now owns 179,497 shares of the company’s stock, valued at $2,064,215.50. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Several hedge funds recently added to or reduced their stakes in OMER. Bank of Montreal Can increased its stake in Omeros Corporation by 52.0% in the fourth quarter. Bank of Montreal Can now owns 1,327,706 shares of the biopharmaceutical company’s stock worth $20,885,000 after buying an additional 454,055 shares in the last quarter. Mutual of America Capital Management LLC increased its position in shares of Omeros Corporation by 0.6% in the fourth quarter. Mutual of America Capital Management LLC now owns 116,171 shares of the biopharmaceutical company’s stock worth $1,827,000 after buying an additional 694 shares during the period. California State Teachers Retirement System increased its position in shares of Omeros Corporation by 1.8% in the fourth quarter. California State Teachers Retirement System now owns 70,144 shares of the biopharmaceutical company’s stock worth $1,103,000 after buying an additional 1,249 shares during the period. Finally, Nationwide Fund Advisors increased its position in shares of Omeros Corporation by 183.9% in the fourth quarter. Nationwide Fund Advisors now owns 69,700 shares of the biopharmaceutical company’s stock worth $1,096,000 after buying an additional 45,145 shares during the period.

Omeros Corporation is a biopharmaceutical company engaged in discovering, developing and commercializing small-molecule and protein therapeutics for market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. The Company’s marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens replacement.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.